ClinicalTrials.gg
Active, not recruitingNCT04580498Updated May 19, 2023

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

A Phase 2 interventional study of SHR-1701+Paclitaxel+carboplatin and SHR-1701 in Non-Small-Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-19.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 24 under way, 5 of them phase 3. Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
56th of 203
107 · median 50
Started
2020
with 3 others
Phase 2
115 of 221
7 open now
Primary completion
2023-07
later than 0 of 23 live
Registered
201st of 221
by date

Among the 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 56th largest by enrollment of the 203 interventional ones that give a count, is one of 4 that started in 2020, is one of 115 in phase 2, reaches primary completion later than 0 of the 23 other live ones, and was the 201st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the study and sign the form;
  • 18 to 70 years old, both male and female;
  • score: 0-1
  • histopathologically or confirmed, inoperable stage III squamous cell or non-squamous cell lung cancer;
  • subjects who can provide fresh or ;
  • available;
  • Major organ function is basically normal;
  • Non-surgically sterile female subjects of childbearing age must have a negative serum HCG test before randomization;

Exclusion criteria

Exclusion Criteria:

  • or cytologically confirmed mixed SCLC and NSCLC;
  • subjects who have malignant pleural effusion;
  • Previous systemic anti-tumor therapy for NSCLC;
  • Previous thoracic radiotherapy;
  • Subjects who participated in other clinical trials within 4 weeks or 5 drug half-lives(whichever is shorter) before the first dose.
  • Systemic immunostimulant therapy before the first dose;
  • Systemic therapy before the first dose or were expected to require systemic immunosuppressive drugs during the study treatment;
  • Subjects with diseases;
  • Other malignant tumors other than non-small cell lung cancer within 5 years before screening;
  • Known or suspected interstitial pneumonia;
  • Other moderate to severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity and seriously affect respiratory function;
  • Severe cardiovascular and cerebrovascular diseases;
  • bleeding symptoms or significant bleeding tendency within 1 month before the first dose;
  • Arteriovenous thrombotic events within 3 months before the first dose;
  • Positive test;
  • Active or C;
  • Evidence of active tuberculosis infection within 1 year before the first dose;
  • Serious infection within 4 years before the first dose;
  • History of attenuated 28 days before the first dose or expected to receive attenuated live vaccination during the study;
  • Major surgeries other than diagnosis or within 28 days prior to first dose;
  • Previous or planned bone marrow transplantation or solid organ transplantation;
  • History of severe allergic reactions to other monoclonal antibodies/fusion proteins;
  • Allergic to any component of the randomized treatment regimen;
  • Female subjects who are pregnant, lactating, or planning to get pregnant during the study period;
  • Subjects who has a known history of psychotropic drug abuse, alcoholism, or drug abuse
  • Presence of other conditions that, in the opinion of the investigator, would make participation in this clinical trial inappropriate.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Treatment group A

    SHR-1701+Paclitaxel+carboplatin

    Drug: SHR-1701+Paclitaxel+carboplatin

  • Experimental
    Treatment group B

    SHR-1701

    Drug: SHR-1701

Interventions

  • DrugSHR-1701+Paclitaxel+carboplatin

    Drug pages: SHR-1701 · Paclitaxel · Carboplatin

    Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5

  • Drug: SHR-1701 30mg/kg

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate

    Time frame: From the initiation of the first dose to 3 years

  2. EFS

    event free survival

    Time frame: From the initiation of the first dose to 3 years

Secondary outcomes

  1. OS

    overall survival

    Time frame: From the initiation of the first dose to 3 years

  2. EFS rate

    event free survival rate

    Time frame: From the initiation of the first dose to 3 years

  3. TDDM

    time to death or distant metastasis

    Time frame: From the initiation of the first dose to 3 years

  4. Adverse events(AEs)

    Incidence of treatment-related AEs

    Time frame: From the initiation of the first dose to 90 days after the last dose

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jul 2023, 32 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 32 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Oct 8, 2020
StartActual
Nov 10, 2020
Primary completionEst.
Jul 15, 2023
CompletionEst.
Mar 1, 2025
Last update
May 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04580498
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Nov 10, 2020
Primary completion
Jul 15, 2023 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
May 19, 2023

Study contacts

Yilong Wu, MD
principal investigator · Guangdong Provincial People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SHR-1701 · Paclitaxel · Carboplatin

Start the discussion